Who
William Enright
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Barinthus Biotherapeutics; Director, Bullfrog AI Holdings; President and CEO, Altimmune.
In numbers
- Trades disclosed
- 45
- Buys
- 2
- Sells
- 1
- Bought
- $21K
- Sold
- $36K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 4 May 2017
- Last trade
- 9 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —728,454 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —514,923 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —176,130 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —176,130 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —359,605 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —440,000 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —443,981 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —600,000 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —359,605 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —440,000 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —443,981 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —600,000 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —728,454 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —514,923 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | BFRG Bullfrog AI HoldingsBiotechnology | SEC FORM 4 Code A | —5,710 at $0.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | BFRG Bullfrog AI HoldingsBiotechnology | SEC FORM 4 Code A | —2,813 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
News
Comparing Bullfrog AI (NASDAQ:BFRG) & iSpecimen (NASDAQ:ISPC)BFRG · tickerreport.com · 8 Oct 2026BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive DisorderBFRG · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name William Enright; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.